Abstract 5187
Background
The practice of oncology is challenging, especially when dealing with terminally ill patients and end of life. This is not without an emotional impact on oncologists, with potential negative effect on patient care and personal lives. We aimed to outline the main factors that makes of patients’ death an emotionally difficult experience, and to identify practical coping strategies.
Methods
An online survey was completed by 128 oncologists from three North African countries and France, on March-April 2019. All surveys were anonymous and confidential. The questionnaire included socio-demographic information, and sections about patients’ death and coping strategies.
Results
Most respondents were female (83.5%) and young oncologists (20-40 years-old), with less than 10 years professional experience (85.3%), but seeing more than 50 patients per week, and experiencing 0-2 deaths per month. They were mostly from Tunisia (n = 99), Morocco (n = 25), Algeria (n = 2) and France (n = 2). The majority was medical oncologists (57.9%), then radiation oncologists (29.4%). More than two-thirds of the oncologists reported that young age, long-term relationship and family denial towards the prognosis were the main factors making death or therapeutic failure announcement the most difficult. Unexpected evolution leading to death, and the non-access to more effective treatment in our countries had an emotional impact on 70% of the oncologists. A variety of coping strategies was identified: mainly peer support from colleagues and/or family and friends (53.5%), practicing hobbies (39.4%), seeking support in praying and faith (26.3%). Addictive behavior and/or medications were reported in 9.1%, significantly in single respondents (p 0.051). A majority (n = 83) reported a change in their character noticed by their families since the practice of oncology. The oncologists expressed becoming better able to set priorities (48%), more humble and human (61.4%) and motivated to improve their quality of health care (33.9%).
Conclusions
Dealing with patients’ death and confronting therapeutic failure have obviously an effect on oncologists’ personal life. We need to be aware of this issue, and to propose different coping strategies and interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract